Gapping up
News:
- REPL +64% (Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025; FDA accepted the resubmission of the Biologics License Application for RP1 in combination with nivolumab for the treatment of advanced melanoma)
- CELC +51.8% (Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial; Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial)
- CRBP +18.9% (Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25)
- UAMY +17.8% (files for $400 mln common stock offering; proposes acquisition of Australia's Larvotto Resources)
- DVLT +16.2% (files for 5 mln share common stock offering by selling shareholders)
- GRAL +14.1% (results Show Galleri Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings; enters private placement expected to result in gross proceeds of ~$325.0 million)
- RAPT +9.5% (to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria)
- AUTL +6.8% (Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis)
- KURA +6.1% (Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress) NCNA +5.7% (Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025)
- MESO +4.7% (reports Ryoncil Net Revenues)
- NRIX +3.7% (Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607)
- IDYA +3.6% (reports positive median overall survival data from phase 2 trial of the Darovasertib and Crizotinib Combination in first-line metastatic uveal melanoma at the 2025 Society for Melanoma Research Congress)
- APLD +3.6% (filed an amendment to the Certificate of the Designations, Powers, Preferences and Rights of Series G Convertible Preferred Stock)
- KROS +3.4% (commences issuer tender offer to repurchase up to $194.4 million shares)
- SMLR +2.5% (CFO Renae Cormier to step down)
- FFAI +2.3% (Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update)
- IRON +2.1% (announces proposed public offering of common stock and pre-funded warrants)
- GKOS +2.1% (receives FDA approval for Epioxa)
- ARVN +2% (Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy)
- NUTX +2% (reports corporate update; significant year-over-year growth in patient volume and cash collections)
- ENTA +1.7% (Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323)
- ARES +1.5% (LenderMAC enters into strategic relationship with Ares to expand origination and non-QM capabilities)
- NVO +1.5% ( FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes)
- LHX +1.4% (The Republic of Korea selects L3Harris for Airborne Early Warning and Control Aircraft Program)
- CORT +1.3% (Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment)
- BA +1.2% (report that FAA has approved increase of 737 MAX production to 42/month from 38/month, according to CNBC)
- CALX +1% (announces that ALLO Communications has launched Smart Schools, an innovative program built on Calix SmartTown for Education and fully integrated with the Calix Broadband Platform)